Comparative Pharmacology
Head-to-head clinical analysis: ARICEPT ODT versus RAZADYNE ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARICEPT ODT versus RAZADYNE ER.
ARICEPT ODT vs RAZADYNE ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reversible acetylcholinesterase inhibitor, increasing acetylcholine concentration in the synaptic cleft of central cholinergic neurons.
Reversible, competitive acetylcholinesterase inhibitor, increasing acetylcholine concentrations in the synaptic cleft of the central nervous system, particularly enhancing cholinergic neurotransmission in the cerebral cortex and hippocampus.
5 mg orally once daily; may increase to 10 mg once daily after 4-6 weeks.
16 mg orally once daily in the morning; may increase to 24 mg once daily after minimum of 4 weeks; maximum dose 24 mg/day.
None Documented
None Documented
Terminal elimination half-life: 70 hours (range 50-80 hours). Clinical context: Steady-state achieved in 15-21 days; once-daily dosing maintains therapeutic concentrations.
Terminal half-life approximately 7-8 hours; clinical context: supports twice-daily dosing
Renal: 57% (as unchanged drug and metabolites); Fecal: 15%; Biliary: minor
Renal: 95% as unchanged drug and metabolites; Fecal: 5%
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor